Neonc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't

These Nasdaq Stories Are Heating Up

NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech

Targeting The Mutant: NTHI's NEO100 Data Could Open a New Front in the Fight Against Brain Cancer

NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

Wall Street is Watching These Biotechs

NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates